Nuveen Asset Management LLC reduced its position in shares of Allergan PLC. (NYSE:AGN) by 49.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,762 shares of the company’s stock after selling 30,466 shares during the period. Nuveen Asset Management LLC’s holdings in Allergan PLC. were worth $7,589,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. Crestwood Advisors Group LLC bought a new stake in shares of Allergan PLC. during the first quarter valued at about $103,000. Feltz Wealth PLAN Inc. bought a new stake in shares of Allergan PLC. during the first quarter valued at about $107,000. Enterprise Financial Services Corp increased its stake in shares of Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock valued at $110,000 after buying an additional 178 shares during the last quarter. Jacobi Capital Management LLC increased its stake in shares of Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after buying an additional 22 shares during the last quarter. Finally, JNBA Financial Advisors increased its stake in shares of Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares during the last quarter. 84.77% of the stock is currently owned by institutional investors.
Allergan PLC. (NYSE AGN) traded up 0.29% on Friday, hitting $232.88. The company had a trading volume of 1,820,899 shares. The firm has a 50-day moving average price of $245.93 and a 200-day moving average price of $238.13. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80. The firm has a market capitalization of $77.85 billion, a PE ratio of 7.10 and a beta of 1.16.
Allergan PLC. (NYSE:AGN) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. During the same period last year, the firm posted $3.35 earnings per share. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. On average, equities research analysts anticipate that Allergan PLC. will post $16.27 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be paid a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.20%. The ex-dividend date is Wednesday, August 16th. Allergan PLC.’s payout ratio is 9.95%.
COPYRIGHT VIOLATION NOTICE: “Allergan PLC. (AGN) Position Decreased by Nuveen Asset Management LLC” was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/08/12/allergan-plc-agn-position-decreased-by-nuveen-asset-management-llc.html.
Several equities research analysts have recently issued reports on the stock. UBS AG restated a “buy” rating and issued a $275.00 price objective on shares of Allergan PLC. in a research note on Monday, May 15th. BidaskClub downgraded shares of Allergan PLC. from a “buy” rating to a “hold” rating in a research note on Wednesday. Wells Fargo & Company restated an “outperform” rating and issued a $280.00 price objective (up previously from $270.00) on shares of Allergan PLC. in a research note on Wednesday. Mizuho restated a “buy” rating and issued a $267.00 price objective on shares of Allergan PLC. in a research note on Wednesday, August 2nd. Finally, Piper Jaffray Companies restated a “hold” rating and issued a $231.00 price objective on shares of Allergan PLC. in a research note on Friday, July 14th. Eight analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $274.49.
In other news, Director Nesli Basgoz sold 1,889 shares of Allergan PLC. stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $220.45, for a total transaction of $416,430.05. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.36% of the company’s stock.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.